{"gene":"NCR3","run_date":"2026-04-29T11:37:56","timeline":{"discoveries":[{"year":1999,"finding":"NKp30 (NCR3) is a 30-kD triggering receptor selectively expressed on all resting and activated human NK cells, belonging to the immunoglobulin superfamily with a single V-type domain and a charged residue in the transmembrane portion. It associates with CD3ζ chains that become tyrosine phosphorylated upon activation. Encoded by the previously identified 1C7 gene.","method":"Monoclonal antibody generation, molecular cloning, redirected killing assays, masking experiments, biochemical analysis of CD3ζ phosphorylation","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — original molecular characterization with cloning, functional assays, and signaling validation in a highly-cited foundational paper","pmids":["10562324"],"is_preprint":false},{"year":2002,"finding":"NKp30 is the major activating receptor mediating NK cell killing of immature dendritic cells (DCs). Both immature and mature DCs activate resting NK cells, but this DC-stimulating function uses an NKp30-independent mechanism, whereas killing of immature DCs is primarily NKp30-dependent.","method":"Monoclonal antibody masking, NK-DC co-culture cytotoxicity assays, NK cell activation assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — reciprocal functional dissection with blocking antibodies, highly cited, replicated by other labs","pmids":["11828009"],"is_preprint":false},{"year":2001,"finding":"NKp30 does not recognize viral hemagglutinins (influenza HA or Sendai virus HN), distinguishing it from NKp44 and NKp46 which do bind these viral proteins.","method":"Binding assays with NKp30 fusion proteins, NK cell cytotoxicity assays against virus-infected cells","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — direct binding assay, clear negative result confirmed by functional cytotoxicity assays","pmids":["11536166"],"is_preprint":false},{"year":2003,"finding":"TGFβ1 down-regulates NKp30 surface expression at the transcriptional level, leading to impaired NK-mediated killing of dendritic cells. NKp46 expression is not similarly affected.","method":"Flow cytometry for surface expression, transcriptional regulation analysis, NK cytotoxicity assays against DCs and tumor lines","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — transcriptional mechanism identified with functional consequence in cytotoxicity assays, highly cited","pmids":["12646700"],"is_preprint":false},{"year":2004,"finding":"Membrane-associated heparan sulfate proteoglycans (HSPGs), particularly glypican-1, are recognized by NKp30 on target cells; 6-O-sulfation and N-acetylation state of the glucose building unit affect this recognition and NK cell lysis.","method":"NK cytotoxicity assays with CHO cells lacking HS, heparanase treatment, glypican-1 siRNA knockdown, competitive inhibition experiments","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple cell-based approaches, but later work disputed HS as a direct ligand (contested finding)","pmids":["15294952"],"is_preprint":false},{"year":2005,"finding":"NKp30-mediated NK cell lysis of autologous APCs and DCs is dependent on phosphatidylinositol 3-kinase (PI-3K) signaling; PI-3K inhibitors LY294002 and wortmannin reduce NKp30-triggered killing and Akt/PKB activation.","method":"PI-3K inhibitor treatment (LY294002, wortmannin), redirected killing assays, Akt/PKB phosphorylation analysis","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — pharmacological dissection of signaling pathway with multiple inhibitors and functional readouts","pmids":["11385609"],"is_preprint":false},{"year":2005,"finding":"NKp30 engagement induces NK cell secretion of TNFα and IFNγ, which in turn promotes DC maturation. This function is controlled by HLA-specific inhibitory NK receptors (KIR/NKG2A). Perforin-deficient NK cells can still induce cytokine-dependent DC maturation via NKp30, dissecting cytotoxic from cytokine-secretory NKp30 functions.","method":"NKp30-blocking mAb, NK-DC co-culture, cytokine neutralization (anti-TNFα), NK cell supernatant transfer, perforin-deficient NK cell analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including neutralization and genetic model (perforin KO), replicated mechanism","pmids":["15784725"],"is_preprint":false},{"year":2005,"finding":"Human cytomegalovirus pp65 (the main tegument protein) directly and specifically interacts with NKp30, causing dissociation of the associated CD3ζ chain from NKp30 and consequently reducing NK cell cytotoxicity.","method":"Direct binding assays, co-immunoprecipitation, functional NK cytotoxicity assays, CD3ζ dissociation analysis","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1 — direct binding demonstrated, molecular mechanism (CD3ζ dissociation) characterized, highly cited","pmids":["15821739"],"is_preprint":false},{"year":2007,"finding":"The nuclear protein BAT3 (BAG-6/HLA-B-associated transcript 3) is released from tumor cells, binds directly to NKp30, and triggers NKp30-mediated NK cytotoxicity. BAT3 is necessary for tumor rejection in a multiple myeloma model.","method":"Co-immunoprecipitation with NKp30, direct binding assays, tumor rejection model (in vivo), NKp30-blocking assays","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — reciprocal binding confirmed, functional consequence in cytotoxicity and in vivo model","pmids":["18055229"],"is_preprint":false},{"year":2009,"finding":"B7-H6, a novel member of the B7 family, is a tumor cell surface ligand for NKp30 that triggers NKp30-mediated NK cell cytotoxicity and cytokine secretion. B7-H6 is not detected in normal human tissues but is expressed on tumor cells.","method":"Protein identification by mass spectrometry, direct binding assays, NKp30-Fc fusion protein pulldown, NK cell activation assays, flow cytometry of normal vs. tumor tissues","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal methods for ligand identification and functional validation, highly cited foundational paper","pmids":["19528259"],"is_preprint":false},{"year":2009,"finding":"MDSCs from hepatocellular carcinoma patients inhibit NK cell cytotoxicity and cytokine secretion via NKp30 in a cell-contact-dependent but arginase-independent manner.","method":"NK-MDSC co-culture, NKp30-blocking antibody experiments, cytotoxicity assays, cytokine measurement","journal":"Hepatology","confidence":"Medium","confidence_rationale":"Tier 2 — cell-contact and NKp30-blocking dissection, single lab","pmids":["19551844"],"is_preprint":false},{"year":2009,"finding":"NKp30, NKp44, and NKp46 bind to different heparan sulfate/heparin sequences. NKp30 and NKp44 have approximately one order of magnitude higher affinity for synthetic HS/heparin than NKp46. NKp30 and NKp44 prefer highly charged HS structures but with different modification patterns.","method":"Microarray binding experiments, surface plasmon resonance (SPR) with synthetic HS/heparin oligosaccharides","journal":"Journal of proteome research","confidence":"Medium","confidence_rationale":"Tier 1 — SPR with synthetic ligands provides quantitative binding data, single study","pmids":["19196184"],"is_preprint":false},{"year":2011,"finding":"Crystal structure of NKp30 bound to its ligand B7-H6 was determined. NKp30, a CD28 family member, engages B7-H6 using both front and back β-sheets of its Ig-like domain (via the side and face of the β-sandwich), a mode distinct from CTLA-4 and PD-1 inhibitory complexes. B7-H6 contacts NKp30 through CDR-like loops of its V-like domain.","method":"X-ray crystallography of NKp30-B7-H6 complex","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — crystal structure of receptor-ligand complex, first structural characterization of an NCR bound to ligand","pmids":["21422170"],"is_preprint":false},{"year":2011,"finding":"Crystal structure of NKp30 extracellular domain revealed an I-type Ig-like fold structurally distinct from NKp44 and NKp46. Ligand binding involves the F strand and surrounding residues (C strand, CD loop). The N-terminal domain of B7-H6 is sufficient for NKp30 recognition.","method":"X-ray crystallography, peptide epitope mapping, solution binding studies, site-directed mutagenesis of NKp30, cytolytic killing assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus mutagenesis and functional assays in same study","pmids":["21444796"],"is_preprint":false},{"year":2011,"finding":"NKp30-mediated signaling activates the canonical NF-κB pathway in NK cells, leading to IκB degradation and nuclear translocation of p65/p50 NF-κB heterodimer. This activation is blocked by the Syk inhibitor piceatannol.","method":"IκB degradation assays, EMSA, fluorescence microscopy, NF-κB reporter assay, Syk inhibitor treatment, NK-target cell conjugation assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — multiple biochemical and reporter assays identifying downstream signaling pathway","pmids":["18025182"],"is_preprint":false},{"year":2011,"finding":"Poxviral hemagglutinin (VV and ECTV) acts as a novel ligand for NKp30 on infected cells, but unlike NKp46 activation, VV HA blocks NKp30-triggered NK activation, representing an immune escape mechanism at late stages of infection.","method":"NCR-CD3ζ reporter cell assays, selectively silenced NCR expression (siRNA), recombinant soluble HA binding, NK cytotoxicity assays","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 2 — reporter assay system plus siRNA knockdown plus direct binding, mechanistic dissection of ligand-dependent activation vs. inhibition","pmids":["21901096"],"is_preprint":false},{"year":2012,"finding":"NKp30 is required for NK cell-fungal conjugate formation, PI3K signaling, and perforin release to mediate recognition and killing of fungal pathogens Cryptococcus and Candida.","method":"Unbiased receptor identification, NKp30-blocking antibodies, PI3K signaling assays, perforin release assays, conjugate formation assays","journal":"Cell host & microbe","confidence":"High","confidence_rationale":"Tier 2 — unbiased identification plus mechanistic pathway dissection with multiple functional readouts","pmids":["24139398"],"is_preprint":false},{"year":2012,"finding":"NKp30 accumulates at the immune synapse interface between NK92 cells and HeLa tumor cells together with LFA-1. NKp30 blockade inhibits degranulation, cytotoxicity, and cytokine secretion but does not prevent NK-target cell conjugation. NKp30 ligation activates the Erk1/2 signaling pathway.","method":"Confocal microscopy of NK immunological synapse, NKp30 blocking antibody, Erk1/2 phosphorylation analysis, degranulation assays","journal":"Immunological investigations","confidence":"Medium","confidence_rationale":"Tier 2 — direct imaging plus signaling dissection, single lab","pmids":["22221078"],"is_preprint":false},{"year":2012,"finding":"NKp30 is required for oHSV-triggered NK cell killing of glioblastoma cells; oHSV infection upregulates NKp30 and NKp46 ligands on glioblastoma cells. Ncr1-/- mice show increased HSV titers and improved oHSV efficacy.","method":"NKp30/NKp46 blocking antibodies, Ncr1-/- mouse model, NK adoptive transfer, in vitro killing assays","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic model (Ncr1 KO) combined with in vitro and in vivo functional assays","pmids":["23178246"],"is_preprint":false},{"year":2012,"finding":"NKp30 engagement on Vδ1 T cells triggers production of CCL3/MIP-1α, CCL4/MIP-1β, and CCL5/RANTES (but not CXCL12), and this chemokine secretion suppresses CCR5-tropic HIV-1 replication in CD4+/CCR5+ cells.","method":"NKp30 blocking and cross-linking assays on Vδ1 T cells, chemokine measurement, HIV-1 replication assays in CD4+ PM1 cells","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — gain-of-function (receptor ligation) and loss-of-function (blocking) with defined functional readouts, single lab","pmids":["22403253"],"is_preprint":false},{"year":2013,"finding":"BAG-6 C-terminal fragment (residues 686-936) forms a noncovalent dimer and is sufficient for high-affinity binding to NKp30 (KD < 100 nM). This fragment inhibits NKp30-dependent signaling, IFN-γ release, and NK cell degranulation in the presence of tumor target cells.","method":"Domain mapping, recombinant protein production, biophysical binding assays, NK cell functional assays (IFN-γ, degranulation)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with defined domain, quantitative KD measurement, functional validation","pmids":["24133212"],"is_preprint":false},{"year":2013,"finding":"B7-H6 expression is induced on proinflammatory CD14+CD16+ monocytes and neutrophils by TLR ligands or proinflammatory cytokines (IL-1β, TNFα), extending its role beyond tumor immunosurveillance to inflammatory/infectious conditions.","method":"Flow cytometry, in vitro stimulation assays, in vivo patient sample analysis","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro mechanistic pathway identification confirmed with in vivo human samples","pmids":["23687088"],"is_preprint":false},{"year":2013,"finding":"HDAC inhibitors (pan- or class I, particularly HDAC2/3) downregulate B7-H6 surface expression by reducing histone acetylation at the B7-H6 promoter, leading to decreased NKp30-dependent NK cell effector functions.","method":"HDAC inhibitor treatment, siRNA knockdown of HDAC2/3, luciferase reporter assay, chromatin immunoprecipitation (ChIP), NK cell functional assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — ChIP and reporter assays directly identify epigenetic regulation mechanism, confirmed with siRNA and pharmacological inhibition","pmids":["23801635"],"is_preprint":false},{"year":2014,"finding":"Tumor cell shedding of B7-H6 is mediated by cell surface metalloproteinases ADAM-10 and ADAM-17. Inhibiting this shedding increases surface B7-H6 and enhances NKp30-mediated NK cell activation.","method":"Pharmacological ADAM inhibitors, siRNA knockdown of ADAM-10 and ADAM-17, flow cytometry for surface B7-H6, NK cell activation assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — both pharmacological and genetic approaches identify specific proteases; functional consequence confirmed","pmids":["24780758"],"is_preprint":false},{"year":2014,"finding":"Tumor-released soluble Galectin-3 directly binds to NKp30 (confirmed by SPR) and inhibits NKp30-mediated but not NKG2D-mediated NK cytolysis. Genetic knockdown of Galectin-3 increases tumor sensitivity to NK killing in vitro and in xenograft models.","method":"NKp30-Fc immunoprecipitation, surface plasmon resonance, NK-tumor co-culture assays, shRNA knockdown, xenograft model with NK adoptive transfer","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — direct binding by SPR, receptor-specific functional dissection, in vivo validation","pmids":["25315772"],"is_preprint":false},{"year":2007,"finding":"NKp30 glycosylation state affects its binding to heparan sulfate; N-linked glycans on NKp30 can occlude the HS binding site. Removal of N-linked glycans restores heparan sulfate-dependent binding to tumor cells. Soluble heparan sulfate enhances IFNγ secretion by NKp30-activated NK cells.","method":"Enzymatic deglycosylation, binding assays with multiple recombinant NKp30 forms, SPR, NK cell IFNγ assay","journal":"Glycobiology","confidence":"Medium","confidence_rationale":"Tier 1 — biochemical demonstration that glycosylation regulates ligand access, but HS as physiological ligand remains contested","pmids":["18006589"],"is_preprint":false},{"year":2012,"finding":"The stalk region of NKp30 (flexible region between ectodomain and transmembrane domain) is an important but previously unrecognized module for ligand recognition and signaling. Glycosylation at three N-linked sites differentially affects ligand binding affinity and signaling; the degree of glycosylation provides a switch modulating NKp30 ligand binding properties.","method":"NKp30-Fc fusion protein panel, mutational analysis of glycosylation sites, cellular binding assays, functional signaling assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis of defined glycosylation sites combined with binding and signaling assays","pmids":["22807449"],"is_preprint":false},{"year":2007,"finding":"NKp30-mediated NK killing of filovirus-infected dendritic cells is dependent on NKp30 upregulation; gene expression knockdown directly linked NK lysis of infected DCs to NKp30 activation. Killing proceeds via perforin and CD95L mechanisms.","method":"Gene expression knockdown (siRNA), cytotoxicity assays, perforin/CD95L blocking","journal":"Cellular microbiology","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA knockdown with functional cytotoxicity readout, single lab","pmids":["17381429"],"is_preprint":false},{"year":2008,"finding":"In uterine decidual NK cells, NKp30 engagement (but not NKp46) triggers production of IFNγ, TNFα, MIP-1α, MIP-1β, and GM-CSF, while NKp46 (but not NKp30) engagement triggers cytotoxicity (calcium mobilization, perforin polarization, granule exocytosis). This demonstrates a differential role for NKp30 vs. NKp46 in cytokine vs. cytotoxic functions in decidual NK cells.","method":"Multicolor flow cytometry, mAb-specific receptor engagement, calcium mobilization assay, perforin polarization assay, granule exocytosis assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — receptor-specific engagement with multiple orthogonal functional readouts definitively dissecting roles of NKp30 vs. NKp46","pmids":["18713971"],"is_preprint":false},{"year":2007,"finding":"NKp30 directly mediates NK cell recognition of P. falciparum-parasitized erythrocytes via interaction with the DBL-1α domain of PfEMP-1. This interaction leads to perforin production and granzyme B release. Pre-treatment of NK cells with DBL-1α peptides abolishes both interaction and killing.","method":"NKp30-Ig fusion protein binding assays, competitive peptide inhibition, perforin/granzyme B release assays","journal":"The Journal of infectious diseases","confidence":"Medium","confidence_rationale":"Tier 2 — direct binding assays with functional consequence, single lab","pmids":["17436233"],"is_preprint":false},{"year":2007,"finding":"NKp30-mediated killing in NK cells requires RAB27A function, as NK killing via NKp30 (but not CD16) is impaired in Griscelli syndrome patients with RAB27A mutations. CD16 triggers Vav1 phosphorylation whereas NKp30 does not, demonstrating distinct downstream signaling pathways.","method":"Patient NK cells from Griscelli syndrome (RAB27A mutation), redirected killing assays, phosphorylation analysis of Vav1","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — natural genetic loss-of-function (disease model) combined with signaling analysis, clean dissection of two receptor pathways","pmids":["17255357"],"is_preprint":false},{"year":2015,"finding":"NKp30 is expressed on a subset of human ILC2s and upon interaction with its cognate ligand B7-H6 induces rapid production of type 2 cytokines. This activation can be blocked by NKp30-blocking antibody or the inhibitory ligand galectin-3.","method":"Flow cytometry, NKp30-B7-H6 co-culture, NKp30-blocking antibody, galectin-3 inhibition, cytokine measurement","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — gain-of-function (ligand stimulation) and loss-of-function (blocking) with functional cytokine readout, single lab","pmids":["26582946"],"is_preprint":false},{"year":2016,"finding":"The proto-oncogene Myc (c-Myc and N-Myc) drives B7-H6 expression by binding a functional site in the B7-H6 promoter. Inhibition or knockdown of c-Myc/N-Myc decreases B7-H6 expression and impairs NKp30-mediated NK cell degranulation.","method":"Luciferase reporter assays, chromatin immunoprecipitation (ChIP), c-Myc/N-Myc siRNA/shRNA, pharmacological c-Myc inhibition, NK degranulation assay","journal":"Oncoimmunology","confidence":"High","confidence_rationale":"Tier 1 — ChIP and reporter assays directly map Myc binding site in B7-H6 promoter, confirmed with genetic and pharmacological knockdown","pmids":["27622013"],"is_preprint":false},{"year":2017,"finding":"NKp30-B7H6 interaction activates ILC2s to secrete IL-13, which in turn activates monocytic MDSCs in acute promyelocytic leukemia, forming an immunosuppressive axis. Disrupting this axis by blocking PGD2, IL-13, or NKp30 restores immune cell levels and improves survival.","method":"Patient sample analysis, blocking antibodies against PGD2, NKp30, IL-13, in vivo survival analysis, flow cytometry","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — pathway blocking experiments with functional readouts in patient samples and in vivo model, single lab","pmids":["28928446"],"is_preprint":false},{"year":2020,"finding":"NKp30 forms oligomers dependent on its N-glycosylation. NKp30 expressed with simple N-glycans forms oligomers, but enzymatic deglycosylation reduces NKp30 to monomers. Crystal structure of glycosylated NKp30-B7-H6 complex revealed a glycosylation-induced mode of NKp30 dimerization. The stalk region and glycosylation affect ligand affinity.","method":"X-ray crystallography, enzymatic deglycosylation, size exclusion chromatography, binding affinity assays","journal":"Cancers","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus biochemical deglycosylation demonstrating glycan-dependent oligomerization","pmids":["32708305"],"is_preprint":false},{"year":2018,"finding":"NK cells lyse Th2-polarizing DCs via NKp30 and DNAM-1. NK cell MTOC polarization and LFA-1 accumulation at the immune synapse occurs with immature and Th2-polarizing DCs (but not Th1-polarizing DCs), indicating assembly of an activating NK synapse. Antibody blockade of NKp30 or DNAM-1 abrogates lysis.","method":"Confocal microscopy, time-lapse live-cell microscopy, antibody blocking of NKp30 and DNAM-1, degranulation assays","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — receptor blocking with imaging of synapse formation, single lab","pmids":["30120122"],"is_preprint":false},{"year":2019,"finding":"In hepatocellular carcinoma, NKp30-positive NK cells have reduced expression of immunostimulatory NCR3 splice variants and increased expression of inhibitory variants. Exposure of NK cells to B7-H6-expressing HCC cells down-modulates NKp30, an effect prevented by siRNA-mediated B7-H6 knockdown, suggesting chronic ligand engagement drives inhibitory NKp30 isoform expression.","method":"Flow cytometry, RT-PCR splice variant analysis, NK-HCC cell co-culture, siRNA knockdown of B7-H6, tumor-infiltrating lymphocyte analysis","journal":"Hepatology","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA rescue experiment combined with splice variant profiling and functional assays, single lab","pmids":["30153337"],"is_preprint":false},{"year":2018,"finding":"IL-15 can de novo induce NKp30 expression in a population of CD8+ T cells. The adaptor FcεRIγ is concomitantly induced and is required for NKp30 cell-surface expression and function in these CD8+ T cells. FcεRIγ expression requires promoter demethylation, and is accompanied by acquisition of Syk and PLZF.","method":"Flow cytometry, in vitro IL-15 stimulation, FcεRIγ knockdown/overexpression, promoter methylation analysis, xenograft tumor model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — genetic dissection of adaptor requirement with multiple orthogonal methods and in vivo validation","pmids":["29895693"],"is_preprint":false},{"year":2024,"finding":"IL-2 is specifically required for NKp30 (but not NKp46) surface expression and NKp30-dependent NK cell cytotoxicity against myeloid leukemia cells. IL-2 deprivation selectively downregulates NKp30 despite shared adaptor requirements with NKp46. Ectopic overexpression of immunostimulatory NKp30 isoforms (NKp30a or NKp30b) rescues NK cell cytotoxicity against B7-H6-expressing tumor cells in vivo without IL-2.","method":"IL-2 deprivation assays, NKp30 isoform overexpression, NK92/NK92MI cell comparison, in vivo xenograft model","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic overexpression rescue combined with in vivo validation, single lab","pmids":["38698855"],"is_preprint":false}],"current_model":"NKp30 (NCR3/CD337) is a type I transmembrane immunoglobulin superfamily receptor (single V-type Ig domain, charged transmembrane residue) constitutively expressed on all human NK cells that signals through associated CD3ζ and FcεRIγ adaptors to activate PI3K/Akt, Erk1/2, Syk, and canonical NF-κB pathways, mediating NK cytotoxicity (RAB27A-dependent degranulation) and cytokine secretion (TNFα, IFNγ, CC-chemokines) upon engagement of tumor/stress ligands (B7-H6, BAT3/BAG-6, galectin-3) or pathogen-derived proteins (CMV pp65, poxviral HA as inhibitory ligand); NKp30's activity is tuned by N-glycosylation-dependent oligomerization and stalk-region contributions to ligand recognition, while its ligand engagement is regulated at multiple levels including TGFβ1-mediated transcriptional suppression, HDAC/Myc-driven B7-H6 expression, and ADAM10/17-mediated ectodomain shedding of B7-H6."},"narrative":{"teleology":[{"year":1999,"claim":"Identification of NKp30 as a novel NK-specific activating receptor resolved how NK cells use non-MHC-restricted Ig-superfamily receptors coupled to CD3ζ ITAM signaling to trigger cytotoxicity.","evidence":"Monoclonal antibody screening, molecular cloning, redirected killing assays, and CD3ζ phosphorylation analysis in human NK cells","pmids":["10562324"],"confidence":"High","gaps":["Cellular ligand(s) unidentified","Contribution of FcεRIγ adaptor not yet tested","In vivo relevance not established"]},{"year":2002,"claim":"Establishing NKp30 as the dominant receptor for NK killing of immature dendritic cells placed it at the interface of innate and adaptive immunity, showing NK cells edit the DC repertoire through NKp30.","evidence":"Blocking antibody experiments in NK–DC co-culture cytotoxicity assays","pmids":["11828009"],"confidence":"High","gaps":["DC-expressed ligand for NKp30 unknown","Mechanism distinguishing immature from mature DC recognition unresolved"]},{"year":2005,"claim":"Dissection of NKp30 downstream signaling through PI3K/Akt and its dual cytotoxic/cytokine-secretory functions revealed that NKp30 activates both degranulation and TNFα/IFNγ production that drives DC maturation, with the cytokine arm operating independently of perforin.","evidence":"PI3K inhibitors (LY294002, wortmannin) in redirected killing and Akt phosphorylation assays; perforin-deficient NK cell analysis; cytokine neutralization in NK–DC co-cultures","pmids":["11385609","15784725"],"confidence":"High","gaps":["Contribution of Syk, Erk, NF-κB pathways not yet mapped","Adaptor chain requirements beyond CD3ζ not defined"]},{"year":2005,"claim":"Discovery that CMV pp65 directly binds NKp30 and dissociates CD3ζ provided the first example of a viral immune evasion mechanism targeting an NCR at the adaptor-coupling level.","evidence":"Direct binding assays, co-immunoprecipitation, CD3ζ dissociation analysis, functional NK cytotoxicity assays","pmids":["15821739"],"confidence":"High","gaps":["Structural basis of pp65–NKp30 interaction unknown","Whether other herpesviruses use analogous mechanisms untested"]},{"year":2007,"claim":"Identification of BAT3/BAG-6 as an NKp30 ligand released by tumor cells, and demonstration that RAB27A-dependent degranulation is selectively required for NKp30- but not CD16-mediated killing, defined both a tumor ligand and a unique granule-release pathway for this receptor.","evidence":"Co-IP and direct binding of BAT3 to NKp30 with in vivo tumor rejection model; patient NK cells from Griscelli syndrome (RAB27A mutations) in redirected killing assays with Vav1 phosphorylation analysis","pmids":["18055229","17255357"],"confidence":"High","gaps":["BAT3 release mechanism from tumor cells not characterized","Whether BAT3 and the later-discovered B7-H6 compete for the same binding site unknown"]},{"year":2008,"claim":"Differential receptor engagement studies in decidual NK cells showed NKp30 preferentially triggers cytokine/chemokine secretion (IFNγ, TNFα, MIP-1α/β) whereas NKp46 triggers cytotoxicity, establishing tissue-specific functional specialization of NCRs.","evidence":"Receptor-specific mAb engagement with calcium mobilization, perforin polarization, and granule exocytosis readouts in decidual NK cells","pmids":["18713971"],"confidence":"High","gaps":["Molecular basis for divergent signaling outcomes from NKp30 vs NKp46 despite shared CD3ζ usage unresolved"]},{"year":2009,"claim":"Discovery of B7-H6 as a tumor-restricted surface ligand for NKp30 provided the first defined activating ligand selectively expressed on transformed cells, establishing NKp30 as a bona fide tumor immunosurveillance receptor.","evidence":"Mass spectrometry identification, NKp30-Fc pulldown, direct binding assays, flow cytometry of normal versus tumor tissues","pmids":["19528259"],"confidence":"High","gaps":["Structural basis of NKp30–B7-H6 interaction not yet determined","In vivo anti-tumor role in autologous setting not tested"]},{"year":2011,"claim":"Crystal structures of the NKp30–B7-H6 complex revealed an unconventional binding mode using both front and back β-sheets of the Ig domain, and downstream NF-κB pathway mapping via Syk identified how NKp30 signals activate transcription factors beyond PI3K.","evidence":"X-ray crystallography of NKp30 alone and in complex with B7-H6; IκB degradation, EMSA, NF-κB reporter assays with Syk inhibitor piceatannol","pmids":["21422170","21444796","18025182"],"confidence":"High","gaps":["Whether oligomeric NKp30 binds B7-H6 differently from monomer unknown","Relative contributions of NF-κB vs PI3K vs Erk pathways to specific effector functions unresolved"]},{"year":2011,"claim":"Poxviral hemagglutinin was shown to bind NKp30 yet inhibit rather than activate NK function, demonstrating that ligand identity determines whether NKp30 engagement is activating or inhibitory—a second viral evasion strategy distinct from CMV pp65.","evidence":"NCR-CD3ζ reporter cells, siRNA-mediated NCR silencing, recombinant soluble HA binding, NK cytotoxicity assays","pmids":["21901096"],"confidence":"High","gaps":["Structural basis distinguishing activating vs inhibitory ligand engagement unknown"]},{"year":2012,"claim":"Multiple studies established that N-glycosylation and the stalk region act as a molecular switch controlling NKp30 ligand affinity, while NKp30 accumulates at the immunological synapse and activates Erk1/2, broadening the known signaling repertoire.","evidence":"Mutagenesis of glycosylation sites with binding and signaling assays; confocal microscopy of NK–tumor synapses; Erk1/2 phosphorylation analysis","pmids":["22807449","22221078"],"confidence":"High","gaps":["Which glycan structures at each site tune affinity not determined","Whether stalk-region flexibility differs between NKp30 isoforms untested"]},{"year":2013,"claim":"BAG-6 domain mapping showed that a C-terminal dimeric fragment binds NKp30 with high affinity yet inhibits signaling, while B7-H6 was found to be inducible on inflammatory monocytes/neutrophils and epigenetically regulated by HDACs, revealing that ligand availability is dynamically controlled.","evidence":"Recombinant BAG-6 domain mapping with biophysical KD measurement; flow cytometry of patient monocytes with TLR stimulation; ChIP and luciferase reporter assays for HDAC regulation of B7-H6 promoter","pmids":["24133212","23687088","23801635"],"confidence":"High","gaps":["Whether soluble BAG-6 fragment is generated physiologically unknown","Full epigenetic landscape of B7-H6 regulation incomplete"]},{"year":2014,"claim":"Identification of galectin-3 as an inhibitory NKp30 ligand and ADAM-10/17 as B7-H6 sheddases defined two tumor immune evasion axes that reduce NKp30-mediated immunosurveillance.","evidence":"SPR for galectin-3–NKp30 binding with xenograft validation; pharmacological ADAM inhibitors and siRNA with surface B7-H6 measurement and NK activation assays","pmids":["25315772","24780758"],"confidence":"High","gaps":["Whether galectin-3 and B7-H6 compete for the same NKp30 surface not tested","In vivo therapeutic potential of ADAM inhibition for NKp30-dependent immunity not assessed"]},{"year":2016,"claim":"Myc was identified as a direct transcriptional driver of B7-H6 expression, linking oncogene activation to NKp30 ligand upregulation and providing a mechanistic explanation for tumor-selective B7-H6 expression.","evidence":"ChIP showing Myc binding at B7-H6 promoter, luciferase reporter assays, c-Myc/N-Myc siRNA/shRNA and pharmacological inhibition with NK degranulation readout","pmids":["27622013"],"confidence":"High","gaps":["Whether other oncogenic pathways also drive B7-H6 expression not comprehensively surveyed","Contribution of Myc vs HDAC regulation to B7-H6 levels in specific tumor types unresolved"]},{"year":2018,"claim":"FcεRIγ was shown to be an essential adaptor for NKp30 surface expression and function in IL-15-induced CD8+ T cells, requiring promoter demethylation, establishing that NKp30 function extends beyond NK cells through epigenetic reprogramming of adaptors.","evidence":"FcεRIγ knockdown/overexpression, promoter methylation analysis, flow cytometry, xenograft tumor model","pmids":["29895693"],"confidence":"High","gaps":["Whether FcεRIγ is also limiting for NKp30 on NK cells unresolved","Signaling differences between CD3ζ- and FcεRIγ-coupled NKp30 not defined"]},{"year":2020,"claim":"Crystallography of glycosylated NKp30–B7-H6 complex demonstrated that N-glycans drive NKp30 dimerization, providing a structural basis for how glycosylation-dependent oligomerization tunes receptor sensitivity.","evidence":"X-ray crystallography of glycosylated complex, enzymatic deglycosylation with size-exclusion chromatography and binding affinity measurements","pmids":["32708305"],"confidence":"High","gaps":["Whether glycan-dependent dimers form on live NK cell surfaces unresolved","Functional consequence of oligomerization for threshold signaling not directly tested in cells"]},{"year":2024,"claim":"IL-2 was identified as a selective regulator of NKp30 (but not NKp46) surface expression, and ectopic overexpression of immunostimulatory NKp30 isoforms rescued anti-tumor cytotoxicity independently of IL-2, revealing isoform-specific functional control.","evidence":"IL-2 deprivation assays comparing NKp30 and NKp46, NKp30a/b isoform overexpression, in vivo xenograft model","pmids":["38698855"],"confidence":"Medium","gaps":["Mechanism by which IL-2 selectively controls NKp30 vs NKp46 unclear","Transcriptional vs post-transcriptional regulation of NKp30 isoform switching not fully characterized"]},{"year":null,"claim":"Key unresolved questions include how NKp30 discriminates activating from inhibitory ligands structurally, how glycan-dependent oligomerization on the live cell surface integrates with adaptor recruitment to set signaling thresholds, and the in vivo contributions of individual NKp30 splice variants to tumor immunosurveillance versus immunosuppression.","evidence":"","pmids":[],"confidence":"High","gaps":["No structure of NKp30 bound to an inhibitory ligand (galectin-3, pp65, poxviral HA)","In vivo isoform-specific functions not delineated in genetic models","Relative stoichiometry of CD3ζ vs FcεRIγ in NKp30 complexes on different cell types unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,9,12,14]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,7,37]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,17,26]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,5,6,9,14,16,18]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,14,17]}],"complexes":[],"partners":["B7-H6","BAG6","CD247","FCER1G","LGALS3","ICAM1"],"other_free_text":[]},"mechanistic_narrative":"NKp30 (NCR3/CD337) is an activating natural cytotoxicity receptor of the immunoglobulin superfamily that couples innate immune recognition of tumor cells, pathogen-infected cells, and immature dendritic cells to NK cell cytotoxicity and cytokine secretion. NKp30 contains a single I-type Ig-like ectodomain that engages the tumor-associated ligand B7-H6 via both front and back β-sheets of its β-sandwich, the stress-induced ligand BAT3/BAG-6, and the inhibitory ligand galectin-3, while pathogen-derived proteins such as CMV pp65 and poxviral hemagglutinin subvert signaling by dissociating the CD3ζ adaptor chain or blocking receptor activation [PMID:10562324, PMID:19528259, PMID:21422170, PMID:18055229, PMID:15821739, PMID:25315772]. Upon ligand engagement, NKp30 signals through associated CD3ζ and FcεRIγ adaptors to activate PI3K/Akt, Syk, Erk1/2, and canonical NF-κB pathways, triggering RAB27A-dependent degranulation and secretion of TNF-α, IFN-γ, and CC-chemokines, with N-glycosylation-dependent oligomerization and stalk-region contacts modulating ligand affinity and signaling output [PMID:11385609, PMID:18025182, PMID:17255357, PMID:32708305, PMID:22807449]. NKp30 expression is transcriptionally suppressed by TGF-β1 and selectively maintained by IL-2, while its principal tumor ligand B7-H6 is regulated by Myc-driven transcription, HDAC-dependent chromatin remodeling, and ADAM-10/17-mediated ectodomain shedding, providing multiple layers of immune evasion and activation control [PMID:12646700, PMID:38698855, PMID:27622013, PMID:23801635, PMID:24780758]."},"prefetch_data":{"uniprot":{"accession":"O14931","full_name":"Natural cytotoxicity triggering receptor 3","aliases":["Activating natural killer receptor p30","Natural killer cell p30-related protein","NK-p30","NKp30"],"length_aa":201,"mass_kda":21.6,"function":"Cell membrane receptor of natural killer/NK cells that is activated by binding of extracellular ligands including BAG6 and NCR3LG1. Stimulates NK cells cytotoxicity toward neighboring cells producing these ligands. It controls, for instance, NK cells cytotoxicity against tumor cells. Engagement of NCR3 by BAG6 also promotes myeloid dendritic cells (DC) maturation, both through killing DCs that did not acquire a mature phenotype, and inducing the release by NK cells of TNFA and IFNG which promote DC maturation","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/O14931/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NCR3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NCR3","total_profiled":1310},"omim":[{"mim_id":"613714","title":"NATURAL KILLER CELL CYTOTOXICITY RECEPTOR 3 LIGAND 1; NCR3LG1","url":"https://www.omim.org/entry/613714"},{"mim_id":"611550","title":"NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NCR3","url":"https://www.omim.org/entry/611550"},{"mim_id":"609148","title":"MALARIA, MILD, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/609148"},{"mim_id":"606764","title":"GASTROINTESTINAL STROMAL TUMOR; GIST","url":"https://www.omim.org/entry/606764"},{"mim_id":"606446","title":"SLAM FAMILY, MEMBER 6; SLAMF6","url":"https://www.omim.org/entry/606446"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"bone marrow","ntpm":3.8},{"tissue":"intestine","ntpm":5.2},{"tissue":"lymphoid tissue","ntpm":15.5}],"url":"https://www.proteinatlas.org/search/NCR3"},"hgnc":{"alias_symbol":["1C7","NKp30","CD337"],"prev_symbol":["LY117"]},"alphafold":{"accession":"O14931","domains":[{"cath_id":"2.60.40.10","chopping":"22-129","consensus_level":"high","plddt":95.5576,"start":22,"end":129}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O14931","model_url":"https://alphafold.ebi.ac.uk/files/AF-O14931-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O14931-F1-predicted_aligned_error_v6.png","plddt_mean":83.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NCR3","jax_strain_url":"https://www.jax.org/strain/search?query=NCR3"},"sequence":{"accession":"O14931","fasta_url":"https://rest.uniprot.org/uniprotkb/O14931.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O14931/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O14931"}},"corpus_meta":[{"pmid":"11828009","id":"PMC_11828009","title":"Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells.","date":"2002","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11828009","citation_count":739,"is_preprint":false},{"pmid":"10562324","id":"PMC_10562324","title":"Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells.","date":"1999","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10562324","citation_count":599,"is_preprint":false},{"pmid":"12646700","id":"PMC_12646700","title":"Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12646700","citation_count":581,"is_preprint":false},{"pmid":"19528259","id":"PMC_19528259","title":"The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans.","date":"2009","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19528259","citation_count":544,"is_preprint":false},{"pmid":"19551844","id":"PMC_19551844","title":"Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor.","date":"2009","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/19551844","citation_count":536,"is_preprint":false},{"pmid":"11536166","id":"PMC_11536166","title":"Recognition of viral hemagglutinins by NKp44 but not by NKp30.","date":"2001","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11536166","citation_count":308,"is_preprint":false},{"pmid":"15784725","id":"PMC_15784725","title":"NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15784725","citation_count":302,"is_preprint":false},{"pmid":"15821739","id":"PMC_15821739","title":"Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus.","date":"2005","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15821739","citation_count":283,"is_preprint":false},{"pmid":"18055229","id":"PMC_18055229","title":"Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells.","date":"2007","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/18055229","citation_count":270,"is_preprint":false},{"pmid":"12938217","id":"PMC_12938217","title":"The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44).","date":"2003","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12938217","citation_count":250,"is_preprint":false},{"pmid":"28928446","id":"PMC_28928446","title":"Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28928446","citation_count":202,"is_preprint":false},{"pmid":"21633088","id":"PMC_21633088","title":"Differentiation of human peripheral blood Vδ1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21633088","citation_count":187,"is_preprint":false},{"pmid":"24780758","id":"PMC_24780758","title":"Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24780758","citation_count":171,"is_preprint":false},{"pmid":"23178246","id":"PMC_23178246","title":"NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.","date":"2012","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23178246","citation_count":168,"is_preprint":false},{"pmid":"19531227","id":"PMC_19531227","title":"Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions.","date":"2009","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19531227","citation_count":168,"is_preprint":false},{"pmid":"26137398","id":"PMC_26137398","title":"B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape.","date":"2015","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/26137398","citation_count":151,"is_preprint":false},{"pmid":"19196184","id":"PMC_19196184","title":"Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate/heparin sequences.","date":"2009","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/19196184","citation_count":130,"is_preprint":false},{"pmid":"25877893","id":"PMC_25877893","title":"Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.","date":"2015","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25877893","citation_count":123,"is_preprint":false},{"pmid":"16272287","id":"PMC_16272287","title":"Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16272287","citation_count":122,"is_preprint":false},{"pmid":"23687088","id":"PMC_23687088","title":"Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23687088","citation_count":119,"is_preprint":false},{"pmid":"15294952","id":"PMC_15294952","title":"Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15294952","citation_count":114,"is_preprint":false},{"pmid":"22851709","id":"PMC_22851709","title":"An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22851709","citation_count":114,"is_preprint":false},{"pmid":"23801635","id":"PMC_23801635","title":"Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23801635","citation_count":113,"is_preprint":false},{"pmid":"18713971","id":"PMC_18713971","title":"Critical and differential roles of NKp46- and NKp30-activating receptors expressed by uterine NK cells in early pregnancy.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18713971","citation_count":111,"is_preprint":false},{"pmid":"25315772","id":"PMC_25315772","title":"Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25315772","citation_count":111,"is_preprint":false},{"pmid":"11385609","id":"PMC_11385609","title":"NK cell-mediated lysis of autologous antigen-presenting cells is triggered by the engagement of the phosphatidylinositol 3-kinase upon ligation of the natural cytotoxicity receptors NKp30 and NKp46.","date":"2001","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11385609","citation_count":110,"is_preprint":false},{"pmid":"21168454","id":"PMC_21168454","title":"Reduced frequencies of NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV infection may predict viral clearance.","date":"2010","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/21168454","citation_count":103,"is_preprint":false},{"pmid":"30255106","id":"PMC_30255106","title":"Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer.","date":"2018","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/30255106","citation_count":101,"is_preprint":false},{"pmid":"21422170","id":"PMC_21422170","title":"Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6.","date":"2011","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21422170","citation_count":100,"is_preprint":false},{"pmid":"23884468","id":"PMC_23884468","title":"NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome.","date":"2013","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23884468","citation_count":100,"is_preprint":false},{"pmid":"20812318","id":"PMC_20812318","title":"Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro.","date":"2010","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/20812318","citation_count":97,"is_preprint":false},{"pmid":"24139398","id":"PMC_24139398","title":"The NK receptor NKp30 mediates direct fungal recognition and killing and is diminished in NK cells from HIV-infected patients.","date":"2013","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/24139398","citation_count":94,"is_preprint":false},{"pmid":"22403253","id":"PMC_22403253","title":"Engagement of NKp30 on Vδ1 T cells induces the production of CCL3, CCL4, and CCL5 and suppresses HIV-1 replication.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22403253","citation_count":91,"is_preprint":false},{"pmid":"21901096","id":"PMC_21901096","title":"Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin.","date":"2011","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/21901096","citation_count":88,"is_preprint":false},{"pmid":"21877119","id":"PMC_21877119","title":"B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors.","date":"2011","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/21877119","citation_count":88,"is_preprint":false},{"pmid":"26582946","id":"PMC_26582946","title":"Group 2 Innate Lymphoid Cells Express Functional NKp30 Receptor Inducing Type 2 Cytokine Production.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26582946","citation_count":80,"is_preprint":false},{"pmid":"18092004","id":"PMC_18092004","title":"Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44.","date":"2007","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18092004","citation_count":79,"is_preprint":false},{"pmid":"26472927","id":"PMC_26472927","title":"Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26472927","citation_count":77,"is_preprint":false},{"pmid":"17436233","id":"PMC_17436233","title":"A Duffy binding-like domain is involved in the NKp30-mediated recognition of Plasmodium falciparum-parasitized erythrocytes by natural killer cells.","date":"2007","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/17436233","citation_count":70,"is_preprint":false},{"pmid":"21695691","id":"PMC_21695691","title":"Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment.","date":"2011","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21695691","citation_count":69,"is_preprint":false},{"pmid":"22488247","id":"PMC_22488247","title":"Evolution of the B7 family: co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7's historical relationship with the MHC.","date":"2012","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/22488247","citation_count":66,"is_preprint":false},{"pmid":"15872155","id":"PMC_15872155","title":"NKp30 (NCR3) is a pseudogene in 12 inbred and wild mouse strains, but an expressed gene in Mus caroli.","date":"2005","source":"Molecular biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/15872155","citation_count":66,"is_preprint":false},{"pmid":"15654827","id":"PMC_15654827","title":"Effects of prolactin and cortisol on natural killer (NK) cell surface expression and function of human natural cytotoxicity receptors (NKp46, NKp44 and NKp30).","date":"2005","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15654827","citation_count":62,"is_preprint":false},{"pmid":"29895693","id":"PMC_29895693","title":"Distinct human circulating NKp30+FcεRIγ+CD8+ T cell population exhibiting high natural killer-like antitumor potential.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29895693","citation_count":61,"is_preprint":false},{"pmid":"11745374","id":"PMC_11745374","title":"Identification, molecular cloning and functional characterization of NKp46 and NKp30 natural cytotoxicity receptors in Macaca fascicularis NK cells.","date":"2001","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11745374","citation_count":58,"is_preprint":false},{"pmid":"30153337","id":"PMC_30153337","title":"Deficient Natural Killer Cell NKp30-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma.","date":"2019","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/30153337","citation_count":58,"is_preprint":false},{"pmid":"21444796","id":"PMC_21444796","title":"Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21444796","citation_count":57,"is_preprint":false},{"pmid":"28956765","id":"PMC_28956765","title":"Control of the HIV-1 DNA Reservoir Is Associated In Vivo and In Vitro with NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by Transcriptionally Unique NK Cells.","date":"2017","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/28956765","citation_count":50,"is_preprint":false},{"pmid":"18006589","id":"PMC_18006589","title":"Altered glycosylation of recombinant NKp30 hampers binding to heparan sulfate: a lesson for the use of recombinant immunoreceptors as an immunological tool.","date":"2007","source":"Glycobiology","url":"https://pubmed.ncbi.nlm.nih.gov/18006589","citation_count":49,"is_preprint":false},{"pmid":"27622013","id":"PMC_27622013","title":"The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells.","date":"2016","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/27622013","citation_count":48,"is_preprint":false},{"pmid":"16362817","id":"PMC_16362817","title":"LST1 and NCR3 expression in autoimmune inflammation and in response to IFN-gamma, LPS and microbial infection.","date":"2005","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/16362817","citation_count":48,"is_preprint":false},{"pmid":"23066150","id":"PMC_23066150","title":"Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23066150","citation_count":47,"is_preprint":false},{"pmid":"28197361","id":"PMC_28197361","title":"NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.","date":"2016","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/28197361","citation_count":46,"is_preprint":false},{"pmid":"23960237","id":"PMC_23960237","title":"Hepatitis C virus-infected cells downregulate NKp30 and inhibit ex vivo NK cell functions.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23960237","citation_count":45,"is_preprint":false},{"pmid":"32737988","id":"PMC_32737988","title":"NKp30 - A prospective target for new cancer immunotherapy strategies.","date":"2020","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32737988","citation_count":41,"is_preprint":false},{"pmid":"25991472","id":"PMC_25991472","title":"Expression of NKp30, NKp46 and DNAM-1 activating receptors on resting and IL-2 activated NK cells from healthy donors according to CMV-serostatus and age.","date":"2015","source":"Biogerontology","url":"https://pubmed.ncbi.nlm.nih.gov/25991472","citation_count":41,"is_preprint":false},{"pmid":"33268483","id":"PMC_33268483","title":"Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.","date":"2020","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/33268483","citation_count":40,"is_preprint":false},{"pmid":"17381429","id":"PMC_17381429","title":"NKp30-dependent cytolysis of filovirus-infected human dendritic cells.","date":"2007","source":"Cellular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/17381429","citation_count":39,"is_preprint":false},{"pmid":"18802053","id":"PMC_18802053","title":"Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18802053","citation_count":38,"is_preprint":false},{"pmid":"22807449","id":"PMC_22807449","title":"The stalk domain and the glycosylation status of the activating natural killer cell receptor NKp30 are important for ligand binding.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22807449","citation_count":37,"is_preprint":false},{"pmid":"30870839","id":"PMC_30870839","title":"Dysregulated Expression of Tim-3 and NKp30 Receptors on NK Cells of Patients with Chronic Lymphocytic Leukemia.","date":"2019","source":"Oncology research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/30870839","citation_count":34,"is_preprint":false},{"pmid":"24133212","id":"PMC_24133212","title":"A soluble fragment of the tumor antigen BCL2-associated athanogene 6 (BAG-6) is essential and sufficient for inhibition of NKp30 receptor-dependent cytotoxicity of natural killer cells.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24133212","citation_count":34,"is_preprint":false},{"pmid":"27511738","id":"PMC_27511738","title":"Involvement of NK Cells and NKp30 Pathway in Antisynthetase Syndrome.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27511738","citation_count":33,"is_preprint":false},{"pmid":"12486606","id":"PMC_12486606","title":"Association of HLA-A*3303-B*4403-DRB1*1302 haplotype, but not of TNFA promoter and NKp30 polymorphism, with postherpetic neuralgia (PHN) in the Japanese population.","date":"2002","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/12486606","citation_count":33,"is_preprint":false},{"pmid":"26392331","id":"PMC_26392331","title":"HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26392331","citation_count":33,"is_preprint":false},{"pmid":"23538009","id":"PMC_23538009","title":"Successfully treated HIV-infected patients have differential expression of NK cell receptors (NKp46 and NKp30) according to AIDS status at presentation.","date":"2013","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/23538009","citation_count":31,"is_preprint":false},{"pmid":"15972650","id":"PMC_15972650","title":"Evidence that the cellular ligand for the human NK cell activation receptor NKp30 is not a heparan sulfate glycosaminoglycan.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15972650","citation_count":30,"is_preprint":false},{"pmid":"18025182","id":"PMC_18025182","title":"NKp30 ligation induces rapid activation of the canonical NF-kappaB pathway in NK cells.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18025182","citation_count":29,"is_preprint":false},{"pmid":"36104113","id":"PMC_36104113","title":"Multifunctional NK Cell-Engaging Antibodies Targeting EGFR and NKp30 Elicit Efficient Tumor Cell Killing and Proinflammatory Cytokine Release.","date":"2022","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/36104113","citation_count":29,"is_preprint":false},{"pmid":"26942070","id":"PMC_26942070","title":"Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.","date":"2015","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/26942070","citation_count":28,"is_preprint":false},{"pmid":"33494528","id":"PMC_33494528","title":"Influenza A Virus Hemagglutinin and Other Pathogen Glycoprotein Interactions with NK Cell Natural Cytotoxicity Receptors NKp46, NKp44, and NKp30.","date":"2021","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/33494528","citation_count":26,"is_preprint":false},{"pmid":"28845754","id":"PMC_28845754","title":"Targeting NKG2D and NKp30 Ligands Shedding to Improve NK Cell-Based Immunotherapy.","date":"2016","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28845754","citation_count":25,"is_preprint":false},{"pmid":"26094914","id":"PMC_26094914","title":"NKp30 isoforms in patients with chronic hepatitis C virus infection.","date":"2015","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26094914","citation_count":24,"is_preprint":false},{"pmid":"28123867","id":"PMC_28123867","title":"NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution.","date":"2016","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/28123867","citation_count":23,"is_preprint":false},{"pmid":"32532927","id":"PMC_32532927","title":"PET Imaging of the Natural Killer Cell Activation Receptor NKp30.","date":"2020","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32532927","citation_count":22,"is_preprint":false},{"pmid":"33671836","id":"PMC_33671836","title":"Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33671836","citation_count":22,"is_preprint":false},{"pmid":"17237420","id":"PMC_17237420","title":"Differential NKp30 inducibility in chimpanzee NK cells and conserved NK cell phenotype and function in long-term HIV-1-infected animals.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17237420","citation_count":22,"is_preprint":false},{"pmid":"30120122","id":"PMC_30120122","title":"Human NK Cells Lyse Th2-Polarizing Dendritic Cells via NKp30 and DNAM-1.","date":"2018","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/30120122","citation_count":20,"is_preprint":false},{"pmid":"29163547","id":"PMC_29163547","title":"Natural Killer Cells from the Subcutaneous Adipose Tissue Underexpress the NKp30 and NKp44 in Obese Persons and Are Less Active against Major Histocompatibility Complex Class I Non-Expressing Neoplastic Cells.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29163547","citation_count":20,"is_preprint":false},{"pmid":"32708305","id":"PMC_32708305","title":"Natural Killer Cell Activation Receptor NKp30 Oligomerization Depends on Its N-Glycosylation.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32708305","citation_count":19,"is_preprint":false},{"pmid":"17208487","id":"PMC_17208487","title":"Association analyses of NCR3 polymorphisms with P. falciparum mild malaria.","date":"2006","source":"Microbes and infection","url":"https://pubmed.ncbi.nlm.nih.gov/17208487","citation_count":19,"is_preprint":false},{"pmid":"26284468","id":"PMC_26284468","title":"Coevolution of MHC genes (LMP/TAP/class Ia, NKT-class Ib, NKp30-B7H6): lessons from cold-blooded vertebrates.","date":"2015","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/26284468","citation_count":19,"is_preprint":false},{"pmid":"29055565","id":"PMC_29055565","title":"Characterization of B7H6, an endogenous ligand for the NK cell activating receptor NKp30, reveals the identity of two different soluble isoforms during normal human pregnancy.","date":"2017","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/29055565","citation_count":19,"is_preprint":false},{"pmid":"17255357","id":"PMC_17255357","title":"NK cytotoxicity mediated by CD16 but not by NKp30 is functional in Griscelli syndrome.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17255357","citation_count":19,"is_preprint":false},{"pmid":"34594326","id":"PMC_34594326","title":"NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34594326","citation_count":18,"is_preprint":false},{"pmid":"23802087","id":"PMC_23802087","title":"Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort.","date":"2013","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/23802087","citation_count":18,"is_preprint":false},{"pmid":"26082773","id":"PMC_26082773","title":"First Trimester Pregnancy Loss and the Expression of Alternatively Spliced NKp30 Isoforms in Maternal Blood and Placental Tissue.","date":"2015","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26082773","citation_count":18,"is_preprint":false},{"pmid":"27941937","id":"PMC_27941937","title":"NKp30+ NK cells are associated with HBV control during pegylated-interferon-alpha-2b therapy of chronic hepatitis B.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27941937","citation_count":17,"is_preprint":false},{"pmid":"38372053","id":"PMC_38372053","title":"Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers.","date":"2024","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/38372053","citation_count":16,"is_preprint":false},{"pmid":"27765926","id":"PMC_27765926","title":"NKp44 and NKp30 splice variant profiles in decidua and tumor tissues: a comparative viewpoint.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27765926","citation_count":15,"is_preprint":false},{"pmid":"16821237","id":"PMC_16821237","title":"NKp30 is a functional activation receptor on a subset of rat natural killer cells.","date":"2006","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16821237","citation_count":15,"is_preprint":false},{"pmid":"19580844","id":"PMC_19580844","title":"Analysis of NK cell/DC interaction in NK-type lymphoproliferative disease of granular lymphocytes (LDGL): role of DNAM-1 and NKp30.","date":"2009","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/19580844","citation_count":15,"is_preprint":false},{"pmid":"26241657","id":"PMC_26241657","title":"NKP30-B7-H6 Interaction Aggravates Hepatocyte Damage through Up-Regulation of Interleukin-32 Expression in Hepatitis B Virus-Related Acute-On-Chronic Liver Failure.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26241657","citation_count":15,"is_preprint":false},{"pmid":"33172426","id":"PMC_33172426","title":"B7-H6, an immunoligand for the natural killer cell activating receptor NKp30, reveals inhibitory effects on cell proliferation and migration, but not apoptosis, in cervical cancer derived-cell lines.","date":"2020","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33172426","citation_count":15,"is_preprint":false},{"pmid":"27663271","id":"PMC_27663271","title":"Structural Insights into the Inhibitory Mechanism of an Antibody against B7-H6, a Stress-Induced Cellular Ligand for the Natural Killer Cell Receptor NKp30.","date":"2016","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27663271","citation_count":14,"is_preprint":false},{"pmid":"30325780","id":"PMC_30325780","title":"B7-H6-mediated downregulation of NKp30 in natural killer cells contributes to HIV-2 immune escape.","date":"2019","source":"AIDS (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/30325780","citation_count":14,"is_preprint":false},{"pmid":"10941844","id":"PMC_10941844","title":"Expression and cellular localization of the protein encoded by the 1C7 gene: a recently described component of the MHC.","date":"2000","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/10941844","citation_count":14,"is_preprint":false},{"pmid":"34046711","id":"PMC_34046711","title":"Engineering a natural ligand-based CAR: directed evolution of the stress-receptor NKp30.","date":"2021","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/34046711","citation_count":13,"is_preprint":false},{"pmid":"22221078","id":"PMC_22221078","title":"Important role for NKp30 in synapse formation and activation of NK cells.","date":"2012","source":"Immunological investigations","url":"https://pubmed.ncbi.nlm.nih.gov/22221078","citation_count":13,"is_preprint":false},{"pmid":"38698855","id":"PMC_38698855","title":"Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38698855","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50800,"output_tokens":8832,"usd":0.14244},"stage2":{"model":"claude-opus-4-6","input_tokens":12820,"output_tokens":4219,"usd":0.254362},"total_usd":0.396802,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"NKp30 (NCR3) is a 30-kD triggering receptor selectively expressed on all resting and activated human NK cells, belonging to the immunoglobulin superfamily with a single V-type domain and a charged residue in the transmembrane portion. It associates with CD3ζ chains that become tyrosine phosphorylated upon activation. Encoded by the previously identified 1C7 gene.\",\n      \"method\": \"Monoclonal antibody generation, molecular cloning, redirected killing assays, masking experiments, biochemical analysis of CD3ζ phosphorylation\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original molecular characterization with cloning, functional assays, and signaling validation in a highly-cited foundational paper\",\n      \"pmids\": [\"10562324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"NKp30 is the major activating receptor mediating NK cell killing of immature dendritic cells (DCs). Both immature and mature DCs activate resting NK cells, but this DC-stimulating function uses an NKp30-independent mechanism, whereas killing of immature DCs is primarily NKp30-dependent.\",\n      \"method\": \"Monoclonal antibody masking, NK-DC co-culture cytotoxicity assays, NK cell activation assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal functional dissection with blocking antibodies, highly cited, replicated by other labs\",\n      \"pmids\": [\"11828009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"NKp30 does not recognize viral hemagglutinins (influenza HA or Sendai virus HN), distinguishing it from NKp44 and NKp46 which do bind these viral proteins.\",\n      \"method\": \"Binding assays with NKp30 fusion proteins, NK cell cytotoxicity assays against virus-infected cells\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding assay, clear negative result confirmed by functional cytotoxicity assays\",\n      \"pmids\": [\"11536166\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TGFβ1 down-regulates NKp30 surface expression at the transcriptional level, leading to impaired NK-mediated killing of dendritic cells. NKp46 expression is not similarly affected.\",\n      \"method\": \"Flow cytometry for surface expression, transcriptional regulation analysis, NK cytotoxicity assays against DCs and tumor lines\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — transcriptional mechanism identified with functional consequence in cytotoxicity assays, highly cited\",\n      \"pmids\": [\"12646700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Membrane-associated heparan sulfate proteoglycans (HSPGs), particularly glypican-1, are recognized by NKp30 on target cells; 6-O-sulfation and N-acetylation state of the glucose building unit affect this recognition and NK cell lysis.\",\n      \"method\": \"NK cytotoxicity assays with CHO cells lacking HS, heparanase treatment, glypican-1 siRNA knockdown, competitive inhibition experiments\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple cell-based approaches, but later work disputed HS as a direct ligand (contested finding)\",\n      \"pmids\": [\"15294952\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"NKp30-mediated NK cell lysis of autologous APCs and DCs is dependent on phosphatidylinositol 3-kinase (PI-3K) signaling; PI-3K inhibitors LY294002 and wortmannin reduce NKp30-triggered killing and Akt/PKB activation.\",\n      \"method\": \"PI-3K inhibitor treatment (LY294002, wortmannin), redirected killing assays, Akt/PKB phosphorylation analysis\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — pharmacological dissection of signaling pathway with multiple inhibitors and functional readouts\",\n      \"pmids\": [\"11385609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"NKp30 engagement induces NK cell secretion of TNFα and IFNγ, which in turn promotes DC maturation. This function is controlled by HLA-specific inhibitory NK receptors (KIR/NKG2A). Perforin-deficient NK cells can still induce cytokine-dependent DC maturation via NKp30, dissecting cytotoxic from cytokine-secretory NKp30 functions.\",\n      \"method\": \"NKp30-blocking mAb, NK-DC co-culture, cytokine neutralization (anti-TNFα), NK cell supernatant transfer, perforin-deficient NK cell analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including neutralization and genetic model (perforin KO), replicated mechanism\",\n      \"pmids\": [\"15784725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Human cytomegalovirus pp65 (the main tegument protein) directly and specifically interacts with NKp30, causing dissociation of the associated CD3ζ chain from NKp30 and consequently reducing NK cell cytotoxicity.\",\n      \"method\": \"Direct binding assays, co-immunoprecipitation, functional NK cytotoxicity assays, CD3ζ dissociation analysis\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding demonstrated, molecular mechanism (CD3ζ dissociation) characterized, highly cited\",\n      \"pmids\": [\"15821739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The nuclear protein BAT3 (BAG-6/HLA-B-associated transcript 3) is released from tumor cells, binds directly to NKp30, and triggers NKp30-mediated NK cytotoxicity. BAT3 is necessary for tumor rejection in a multiple myeloma model.\",\n      \"method\": \"Co-immunoprecipitation with NKp30, direct binding assays, tumor rejection model (in vivo), NKp30-blocking assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal binding confirmed, functional consequence in cytotoxicity and in vivo model\",\n      \"pmids\": [\"18055229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"B7-H6, a novel member of the B7 family, is a tumor cell surface ligand for NKp30 that triggers NKp30-mediated NK cell cytotoxicity and cytokine secretion. B7-H6 is not detected in normal human tissues but is expressed on tumor cells.\",\n      \"method\": \"Protein identification by mass spectrometry, direct binding assays, NKp30-Fc fusion protein pulldown, NK cell activation assays, flow cytometry of normal vs. tumor tissues\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods for ligand identification and functional validation, highly cited foundational paper\",\n      \"pmids\": [\"19528259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MDSCs from hepatocellular carcinoma patients inhibit NK cell cytotoxicity and cytokine secretion via NKp30 in a cell-contact-dependent but arginase-independent manner.\",\n      \"method\": \"NK-MDSC co-culture, NKp30-blocking antibody experiments, cytotoxicity assays, cytokine measurement\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cell-contact and NKp30-blocking dissection, single lab\",\n      \"pmids\": [\"19551844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"NKp30, NKp44, and NKp46 bind to different heparan sulfate/heparin sequences. NKp30 and NKp44 have approximately one order of magnitude higher affinity for synthetic HS/heparin than NKp46. NKp30 and NKp44 prefer highly charged HS structures but with different modification patterns.\",\n      \"method\": \"Microarray binding experiments, surface plasmon resonance (SPR) with synthetic HS/heparin oligosaccharides\",\n      \"journal\": \"Journal of proteome research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — SPR with synthetic ligands provides quantitative binding data, single study\",\n      \"pmids\": [\"19196184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Crystal structure of NKp30 bound to its ligand B7-H6 was determined. NKp30, a CD28 family member, engages B7-H6 using both front and back β-sheets of its Ig-like domain (via the side and face of the β-sandwich), a mode distinct from CTLA-4 and PD-1 inhibitory complexes. B7-H6 contacts NKp30 through CDR-like loops of its V-like domain.\",\n      \"method\": \"X-ray crystallography of NKp30-B7-H6 complex\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure of receptor-ligand complex, first structural characterization of an NCR bound to ligand\",\n      \"pmids\": [\"21422170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Crystal structure of NKp30 extracellular domain revealed an I-type Ig-like fold structurally distinct from NKp44 and NKp46. Ligand binding involves the F strand and surrounding residues (C strand, CD loop). The N-terminal domain of B7-H6 is sufficient for NKp30 recognition.\",\n      \"method\": \"X-ray crystallography, peptide epitope mapping, solution binding studies, site-directed mutagenesis of NKp30, cytolytic killing assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus mutagenesis and functional assays in same study\",\n      \"pmids\": [\"21444796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"NKp30-mediated signaling activates the canonical NF-κB pathway in NK cells, leading to IκB degradation and nuclear translocation of p65/p50 NF-κB heterodimer. This activation is blocked by the Syk inhibitor piceatannol.\",\n      \"method\": \"IκB degradation assays, EMSA, fluorescence microscopy, NF-κB reporter assay, Syk inhibitor treatment, NK-target cell conjugation assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple biochemical and reporter assays identifying downstream signaling pathway\",\n      \"pmids\": [\"18025182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Poxviral hemagglutinin (VV and ECTV) acts as a novel ligand for NKp30 on infected cells, but unlike NKp46 activation, VV HA blocks NKp30-triggered NK activation, representing an immune escape mechanism at late stages of infection.\",\n      \"method\": \"NCR-CD3ζ reporter cell assays, selectively silenced NCR expression (siRNA), recombinant soluble HA binding, NK cytotoxicity assays\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reporter assay system plus siRNA knockdown plus direct binding, mechanistic dissection of ligand-dependent activation vs. inhibition\",\n      \"pmids\": [\"21901096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NKp30 is required for NK cell-fungal conjugate formation, PI3K signaling, and perforin release to mediate recognition and killing of fungal pathogens Cryptococcus and Candida.\",\n      \"method\": \"Unbiased receptor identification, NKp30-blocking antibodies, PI3K signaling assays, perforin release assays, conjugate formation assays\",\n      \"journal\": \"Cell host & microbe\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — unbiased identification plus mechanistic pathway dissection with multiple functional readouts\",\n      \"pmids\": [\"24139398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NKp30 accumulates at the immune synapse interface between NK92 cells and HeLa tumor cells together with LFA-1. NKp30 blockade inhibits degranulation, cytotoxicity, and cytokine secretion but does not prevent NK-target cell conjugation. NKp30 ligation activates the Erk1/2 signaling pathway.\",\n      \"method\": \"Confocal microscopy of NK immunological synapse, NKp30 blocking antibody, Erk1/2 phosphorylation analysis, degranulation assays\",\n      \"journal\": \"Immunological investigations\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct imaging plus signaling dissection, single lab\",\n      \"pmids\": [\"22221078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NKp30 is required for oHSV-triggered NK cell killing of glioblastoma cells; oHSV infection upregulates NKp30 and NKp46 ligands on glioblastoma cells. Ncr1-/- mice show increased HSV titers and improved oHSV efficacy.\",\n      \"method\": \"NKp30/NKp46 blocking antibodies, Ncr1-/- mouse model, NK adoptive transfer, in vitro killing assays\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic model (Ncr1 KO) combined with in vitro and in vivo functional assays\",\n      \"pmids\": [\"23178246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NKp30 engagement on Vδ1 T cells triggers production of CCL3/MIP-1α, CCL4/MIP-1β, and CCL5/RANTES (but not CXCL12), and this chemokine secretion suppresses CCR5-tropic HIV-1 replication in CD4+/CCR5+ cells.\",\n      \"method\": \"NKp30 blocking and cross-linking assays on Vδ1 T cells, chemokine measurement, HIV-1 replication assays in CD4+ PM1 cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function (receptor ligation) and loss-of-function (blocking) with defined functional readouts, single lab\",\n      \"pmids\": [\"22403253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BAG-6 C-terminal fragment (residues 686-936) forms a noncovalent dimer and is sufficient for high-affinity binding to NKp30 (KD < 100 nM). This fragment inhibits NKp30-dependent signaling, IFN-γ release, and NK cell degranulation in the presence of tumor target cells.\",\n      \"method\": \"Domain mapping, recombinant protein production, biophysical binding assays, NK cell functional assays (IFN-γ, degranulation)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with defined domain, quantitative KD measurement, functional validation\",\n      \"pmids\": [\"24133212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"B7-H6 expression is induced on proinflammatory CD14+CD16+ monocytes and neutrophils by TLR ligands or proinflammatory cytokines (IL-1β, TNFα), extending its role beyond tumor immunosurveillance to inflammatory/infectious conditions.\",\n      \"method\": \"Flow cytometry, in vitro stimulation assays, in vivo patient sample analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro mechanistic pathway identification confirmed with in vivo human samples\",\n      \"pmids\": [\"23687088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HDAC inhibitors (pan- or class I, particularly HDAC2/3) downregulate B7-H6 surface expression by reducing histone acetylation at the B7-H6 promoter, leading to decreased NKp30-dependent NK cell effector functions.\",\n      \"method\": \"HDAC inhibitor treatment, siRNA knockdown of HDAC2/3, luciferase reporter assay, chromatin immunoprecipitation (ChIP), NK cell functional assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — ChIP and reporter assays directly identify epigenetic regulation mechanism, confirmed with siRNA and pharmacological inhibition\",\n      \"pmids\": [\"23801635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Tumor cell shedding of B7-H6 is mediated by cell surface metalloproteinases ADAM-10 and ADAM-17. Inhibiting this shedding increases surface B7-H6 and enhances NKp30-mediated NK cell activation.\",\n      \"method\": \"Pharmacological ADAM inhibitors, siRNA knockdown of ADAM-10 and ADAM-17, flow cytometry for surface B7-H6, NK cell activation assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — both pharmacological and genetic approaches identify specific proteases; functional consequence confirmed\",\n      \"pmids\": [\"24780758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Tumor-released soluble Galectin-3 directly binds to NKp30 (confirmed by SPR) and inhibits NKp30-mediated but not NKG2D-mediated NK cytolysis. Genetic knockdown of Galectin-3 increases tumor sensitivity to NK killing in vitro and in xenograft models.\",\n      \"method\": \"NKp30-Fc immunoprecipitation, surface plasmon resonance, NK-tumor co-culture assays, shRNA knockdown, xenograft model with NK adoptive transfer\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding by SPR, receptor-specific functional dissection, in vivo validation\",\n      \"pmids\": [\"25315772\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"NKp30 glycosylation state affects its binding to heparan sulfate; N-linked glycans on NKp30 can occlude the HS binding site. Removal of N-linked glycans restores heparan sulfate-dependent binding to tumor cells. Soluble heparan sulfate enhances IFNγ secretion by NKp30-activated NK cells.\",\n      \"method\": \"Enzymatic deglycosylation, binding assays with multiple recombinant NKp30 forms, SPR, NK cell IFNγ assay\",\n      \"journal\": \"Glycobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — biochemical demonstration that glycosylation regulates ligand access, but HS as physiological ligand remains contested\",\n      \"pmids\": [\"18006589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The stalk region of NKp30 (flexible region between ectodomain and transmembrane domain) is an important but previously unrecognized module for ligand recognition and signaling. Glycosylation at three N-linked sites differentially affects ligand binding affinity and signaling; the degree of glycosylation provides a switch modulating NKp30 ligand binding properties.\",\n      \"method\": \"NKp30-Fc fusion protein panel, mutational analysis of glycosylation sites, cellular binding assays, functional signaling assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis of defined glycosylation sites combined with binding and signaling assays\",\n      \"pmids\": [\"22807449\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"NKp30-mediated NK killing of filovirus-infected dendritic cells is dependent on NKp30 upregulation; gene expression knockdown directly linked NK lysis of infected DCs to NKp30 activation. Killing proceeds via perforin and CD95L mechanisms.\",\n      \"method\": \"Gene expression knockdown (siRNA), cytotoxicity assays, perforin/CD95L blocking\",\n      \"journal\": \"Cellular microbiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA knockdown with functional cytotoxicity readout, single lab\",\n      \"pmids\": [\"17381429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"In uterine decidual NK cells, NKp30 engagement (but not NKp46) triggers production of IFNγ, TNFα, MIP-1α, MIP-1β, and GM-CSF, while NKp46 (but not NKp30) engagement triggers cytotoxicity (calcium mobilization, perforin polarization, granule exocytosis). This demonstrates a differential role for NKp30 vs. NKp46 in cytokine vs. cytotoxic functions in decidual NK cells.\",\n      \"method\": \"Multicolor flow cytometry, mAb-specific receptor engagement, calcium mobilization assay, perforin polarization assay, granule exocytosis assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor-specific engagement with multiple orthogonal functional readouts definitively dissecting roles of NKp30 vs. NKp46\",\n      \"pmids\": [\"18713971\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"NKp30 directly mediates NK cell recognition of P. falciparum-parasitized erythrocytes via interaction with the DBL-1α domain of PfEMP-1. This interaction leads to perforin production and granzyme B release. Pre-treatment of NK cells with DBL-1α peptides abolishes both interaction and killing.\",\n      \"method\": \"NKp30-Ig fusion protein binding assays, competitive peptide inhibition, perforin/granzyme B release assays\",\n      \"journal\": \"The Journal of infectious diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding assays with functional consequence, single lab\",\n      \"pmids\": [\"17436233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"NKp30-mediated killing in NK cells requires RAB27A function, as NK killing via NKp30 (but not CD16) is impaired in Griscelli syndrome patients with RAB27A mutations. CD16 triggers Vav1 phosphorylation whereas NKp30 does not, demonstrating distinct downstream signaling pathways.\",\n      \"method\": \"Patient NK cells from Griscelli syndrome (RAB27A mutation), redirected killing assays, phosphorylation analysis of Vav1\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — natural genetic loss-of-function (disease model) combined with signaling analysis, clean dissection of two receptor pathways\",\n      \"pmids\": [\"17255357\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NKp30 is expressed on a subset of human ILC2s and upon interaction with its cognate ligand B7-H6 induces rapid production of type 2 cytokines. This activation can be blocked by NKp30-blocking antibody or the inhibitory ligand galectin-3.\",\n      \"method\": \"Flow cytometry, NKp30-B7-H6 co-culture, NKp30-blocking antibody, galectin-3 inhibition, cytokine measurement\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function (ligand stimulation) and loss-of-function (blocking) with functional cytokine readout, single lab\",\n      \"pmids\": [\"26582946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The proto-oncogene Myc (c-Myc and N-Myc) drives B7-H6 expression by binding a functional site in the B7-H6 promoter. Inhibition or knockdown of c-Myc/N-Myc decreases B7-H6 expression and impairs NKp30-mediated NK cell degranulation.\",\n      \"method\": \"Luciferase reporter assays, chromatin immunoprecipitation (ChIP), c-Myc/N-Myc siRNA/shRNA, pharmacological c-Myc inhibition, NK degranulation assay\",\n      \"journal\": \"Oncoimmunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — ChIP and reporter assays directly map Myc binding site in B7-H6 promoter, confirmed with genetic and pharmacological knockdown\",\n      \"pmids\": [\"27622013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NKp30-B7H6 interaction activates ILC2s to secrete IL-13, which in turn activates monocytic MDSCs in acute promyelocytic leukemia, forming an immunosuppressive axis. Disrupting this axis by blocking PGD2, IL-13, or NKp30 restores immune cell levels and improves survival.\",\n      \"method\": \"Patient sample analysis, blocking antibodies against PGD2, NKp30, IL-13, in vivo survival analysis, flow cytometry\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway blocking experiments with functional readouts in patient samples and in vivo model, single lab\",\n      \"pmids\": [\"28928446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NKp30 forms oligomers dependent on its N-glycosylation. NKp30 expressed with simple N-glycans forms oligomers, but enzymatic deglycosylation reduces NKp30 to monomers. Crystal structure of glycosylated NKp30-B7-H6 complex revealed a glycosylation-induced mode of NKp30 dimerization. The stalk region and glycosylation affect ligand affinity.\",\n      \"method\": \"X-ray crystallography, enzymatic deglycosylation, size exclusion chromatography, binding affinity assays\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus biochemical deglycosylation demonstrating glycan-dependent oligomerization\",\n      \"pmids\": [\"32708305\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NK cells lyse Th2-polarizing DCs via NKp30 and DNAM-1. NK cell MTOC polarization and LFA-1 accumulation at the immune synapse occurs with immature and Th2-polarizing DCs (but not Th1-polarizing DCs), indicating assembly of an activating NK synapse. Antibody blockade of NKp30 or DNAM-1 abrogates lysis.\",\n      \"method\": \"Confocal microscopy, time-lapse live-cell microscopy, antibody blocking of NKp30 and DNAM-1, degranulation assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor blocking with imaging of synapse formation, single lab\",\n      \"pmids\": [\"30120122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In hepatocellular carcinoma, NKp30-positive NK cells have reduced expression of immunostimulatory NCR3 splice variants and increased expression of inhibitory variants. Exposure of NK cells to B7-H6-expressing HCC cells down-modulates NKp30, an effect prevented by siRNA-mediated B7-H6 knockdown, suggesting chronic ligand engagement drives inhibitory NKp30 isoform expression.\",\n      \"method\": \"Flow cytometry, RT-PCR splice variant analysis, NK-HCC cell co-culture, siRNA knockdown of B7-H6, tumor-infiltrating lymphocyte analysis\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA rescue experiment combined with splice variant profiling and functional assays, single lab\",\n      \"pmids\": [\"30153337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IL-15 can de novo induce NKp30 expression in a population of CD8+ T cells. The adaptor FcεRIγ is concomitantly induced and is required for NKp30 cell-surface expression and function in these CD8+ T cells. FcεRIγ expression requires promoter demethylation, and is accompanied by acquisition of Syk and PLZF.\",\n      \"method\": \"Flow cytometry, in vitro IL-15 stimulation, FcεRIγ knockdown/overexpression, promoter methylation analysis, xenograft tumor model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic dissection of adaptor requirement with multiple orthogonal methods and in vivo validation\",\n      \"pmids\": [\"29895693\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"IL-2 is specifically required for NKp30 (but not NKp46) surface expression and NKp30-dependent NK cell cytotoxicity against myeloid leukemia cells. IL-2 deprivation selectively downregulates NKp30 despite shared adaptor requirements with NKp46. Ectopic overexpression of immunostimulatory NKp30 isoforms (NKp30a or NKp30b) rescues NK cell cytotoxicity against B7-H6-expressing tumor cells in vivo without IL-2.\",\n      \"method\": \"IL-2 deprivation assays, NKp30 isoform overexpression, NK92/NK92MI cell comparison, in vivo xenograft model\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic overexpression rescue combined with in vivo validation, single lab\",\n      \"pmids\": [\"38698855\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NKp30 (NCR3/CD337) is a type I transmembrane immunoglobulin superfamily receptor (single V-type Ig domain, charged transmembrane residue) constitutively expressed on all human NK cells that signals through associated CD3ζ and FcεRIγ adaptors to activate PI3K/Akt, Erk1/2, Syk, and canonical NF-κB pathways, mediating NK cytotoxicity (RAB27A-dependent degranulation) and cytokine secretion (TNFα, IFNγ, CC-chemokines) upon engagement of tumor/stress ligands (B7-H6, BAT3/BAG-6, galectin-3) or pathogen-derived proteins (CMV pp65, poxviral HA as inhibitory ligand); NKp30's activity is tuned by N-glycosylation-dependent oligomerization and stalk-region contributions to ligand recognition, while its ligand engagement is regulated at multiple levels including TGFβ1-mediated transcriptional suppression, HDAC/Myc-driven B7-H6 expression, and ADAM10/17-mediated ectodomain shedding of B7-H6.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"NKp30 (NCR3/CD337) is an activating natural cytotoxicity receptor of the immunoglobulin superfamily that couples innate immune recognition of tumor cells, pathogen-infected cells, and immature dendritic cells to NK cell cytotoxicity and cytokine secretion. NKp30 contains a single I-type Ig-like ectodomain that engages the tumor-associated ligand B7-H6 via both front and back β-sheets of its β-sandwich, the stress-induced ligand BAT3/BAG-6, and the inhibitory ligand galectin-3, while pathogen-derived proteins such as CMV pp65 and poxviral hemagglutinin subvert signaling by dissociating the CD3ζ adaptor chain or blocking receptor activation [PMID:10562324, PMID:19528259, PMID:21422170, PMID:18055229, PMID:15821739, PMID:25315772]. Upon ligand engagement, NKp30 signals through associated CD3ζ and FcεRIγ adaptors to activate PI3K/Akt, Syk, Erk1/2, and canonical NF-κB pathways, triggering RAB27A-dependent degranulation and secretion of TNF-α, IFN-γ, and CC-chemokines, with N-glycosylation-dependent oligomerization and stalk-region contacts modulating ligand affinity and signaling output [PMID:11385609, PMID:18025182, PMID:17255357, PMID:32708305, PMID:22807449]. NKp30 expression is transcriptionally suppressed by TGF-β1 and selectively maintained by IL-2, while its principal tumor ligand B7-H6 is regulated by Myc-driven transcription, HDAC-dependent chromatin remodeling, and ADAM-10/17-mediated ectodomain shedding, providing multiple layers of immune evasion and activation control [PMID:12646700, PMID:38698855, PMID:27622013, PMID:23801635, PMID:24780758].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Identification of NKp30 as a novel NK-specific activating receptor resolved how NK cells use non-MHC-restricted Ig-superfamily receptors coupled to CD3ζ ITAM signaling to trigger cytotoxicity.\",\n      \"evidence\": \"Monoclonal antibody screening, molecular cloning, redirected killing assays, and CD3ζ phosphorylation analysis in human NK cells\",\n      \"pmids\": [\"10562324\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular ligand(s) unidentified\", \"Contribution of FcεRIγ adaptor not yet tested\", \"In vivo relevance not established\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Establishing NKp30 as the dominant receptor for NK killing of immature dendritic cells placed it at the interface of innate and adaptive immunity, showing NK cells edit the DC repertoire through NKp30.\",\n      \"evidence\": \"Blocking antibody experiments in NK–DC co-culture cytotoxicity assays\",\n      \"pmids\": [\"11828009\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"DC-expressed ligand for NKp30 unknown\", \"Mechanism distinguishing immature from mature DC recognition unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Dissection of NKp30 downstream signaling through PI3K/Akt and its dual cytotoxic/cytokine-secretory functions revealed that NKp30 activates both degranulation and TNFα/IFNγ production that drives DC maturation, with the cytokine arm operating independently of perforin.\",\n      \"evidence\": \"PI3K inhibitors (LY294002, wortmannin) in redirected killing and Akt phosphorylation assays; perforin-deficient NK cell analysis; cytokine neutralization in NK–DC co-cultures\",\n      \"pmids\": [\"11385609\", \"15784725\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Contribution of Syk, Erk, NF-κB pathways not yet mapped\", \"Adaptor chain requirements beyond CD3ζ not defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Discovery that CMV pp65 directly binds NKp30 and dissociates CD3ζ provided the first example of a viral immune evasion mechanism targeting an NCR at the adaptor-coupling level.\",\n      \"evidence\": \"Direct binding assays, co-immunoprecipitation, CD3ζ dissociation analysis, functional NK cytotoxicity assays\",\n      \"pmids\": [\"15821739\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of pp65–NKp30 interaction unknown\", \"Whether other herpesviruses use analogous mechanisms untested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identification of BAT3/BAG-6 as an NKp30 ligand released by tumor cells, and demonstration that RAB27A-dependent degranulation is selectively required for NKp30- but not CD16-mediated killing, defined both a tumor ligand and a unique granule-release pathway for this receptor.\",\n      \"evidence\": \"Co-IP and direct binding of BAT3 to NKp30 with in vivo tumor rejection model; patient NK cells from Griscelli syndrome (RAB27A mutations) in redirected killing assays with Vav1 phosphorylation analysis\",\n      \"pmids\": [\"18055229\", \"17255357\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"BAT3 release mechanism from tumor cells not characterized\", \"Whether BAT3 and the later-discovered B7-H6 compete for the same binding site unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Differential receptor engagement studies in decidual NK cells showed NKp30 preferentially triggers cytokine/chemokine secretion (IFNγ, TNFα, MIP-1α/β) whereas NKp46 triggers cytotoxicity, establishing tissue-specific functional specialization of NCRs.\",\n      \"evidence\": \"Receptor-specific mAb engagement with calcium mobilization, perforin polarization, and granule exocytosis readouts in decidual NK cells\",\n      \"pmids\": [\"18713971\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for divergent signaling outcomes from NKp30 vs NKp46 despite shared CD3ζ usage unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery of B7-H6 as a tumor-restricted surface ligand for NKp30 provided the first defined activating ligand selectively expressed on transformed cells, establishing NKp30 as a bona fide tumor immunosurveillance receptor.\",\n      \"evidence\": \"Mass spectrometry identification, NKp30-Fc pulldown, direct binding assays, flow cytometry of normal versus tumor tissues\",\n      \"pmids\": [\"19528259\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of NKp30–B7-H6 interaction not yet determined\", \"In vivo anti-tumor role in autologous setting not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Crystal structures of the NKp30–B7-H6 complex revealed an unconventional binding mode using both front and back β-sheets of the Ig domain, and downstream NF-κB pathway mapping via Syk identified how NKp30 signals activate transcription factors beyond PI3K.\",\n      \"evidence\": \"X-ray crystallography of NKp30 alone and in complex with B7-H6; IκB degradation, EMSA, NF-κB reporter assays with Syk inhibitor piceatannol\",\n      \"pmids\": [\"21422170\", \"21444796\", \"18025182\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether oligomeric NKp30 binds B7-H6 differently from monomer unknown\", \"Relative contributions of NF-κB vs PI3K vs Erk pathways to specific effector functions unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Poxviral hemagglutinin was shown to bind NKp30 yet inhibit rather than activate NK function, demonstrating that ligand identity determines whether NKp30 engagement is activating or inhibitory—a second viral evasion strategy distinct from CMV pp65.\",\n      \"evidence\": \"NCR-CD3ζ reporter cells, siRNA-mediated NCR silencing, recombinant soluble HA binding, NK cytotoxicity assays\",\n      \"pmids\": [\"21901096\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis distinguishing activating vs inhibitory ligand engagement unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Multiple studies established that N-glycosylation and the stalk region act as a molecular switch controlling NKp30 ligand affinity, while NKp30 accumulates at the immunological synapse and activates Erk1/2, broadening the known signaling repertoire.\",\n      \"evidence\": \"Mutagenesis of glycosylation sites with binding and signaling assays; confocal microscopy of NK–tumor synapses; Erk1/2 phosphorylation analysis\",\n      \"pmids\": [\"22807449\", \"22221078\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which glycan structures at each site tune affinity not determined\", \"Whether stalk-region flexibility differs between NKp30 isoforms untested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"BAG-6 domain mapping showed that a C-terminal dimeric fragment binds NKp30 with high affinity yet inhibits signaling, while B7-H6 was found to be inducible on inflammatory monocytes/neutrophils and epigenetically regulated by HDACs, revealing that ligand availability is dynamically controlled.\",\n      \"evidence\": \"Recombinant BAG-6 domain mapping with biophysical KD measurement; flow cytometry of patient monocytes with TLR stimulation; ChIP and luciferase reporter assays for HDAC regulation of B7-H6 promoter\",\n      \"pmids\": [\"24133212\", \"23687088\", \"23801635\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether soluble BAG-6 fragment is generated physiologically unknown\", \"Full epigenetic landscape of B7-H6 regulation incomplete\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of galectin-3 as an inhibitory NKp30 ligand and ADAM-10/17 as B7-H6 sheddases defined two tumor immune evasion axes that reduce NKp30-mediated immunosurveillance.\",\n      \"evidence\": \"SPR for galectin-3–NKp30 binding with xenograft validation; pharmacological ADAM inhibitors and siRNA with surface B7-H6 measurement and NK activation assays\",\n      \"pmids\": [\"25315772\", \"24780758\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether galectin-3 and B7-H6 compete for the same NKp30 surface not tested\", \"In vivo therapeutic potential of ADAM inhibition for NKp30-dependent immunity not assessed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Myc was identified as a direct transcriptional driver of B7-H6 expression, linking oncogene activation to NKp30 ligand upregulation and providing a mechanistic explanation for tumor-selective B7-H6 expression.\",\n      \"evidence\": \"ChIP showing Myc binding at B7-H6 promoter, luciferase reporter assays, c-Myc/N-Myc siRNA/shRNA and pharmacological inhibition with NK degranulation readout\",\n      \"pmids\": [\"27622013\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other oncogenic pathways also drive B7-H6 expression not comprehensively surveyed\", \"Contribution of Myc vs HDAC regulation to B7-H6 levels in specific tumor types unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"FcεRIγ was shown to be an essential adaptor for NKp30 surface expression and function in IL-15-induced CD8+ T cells, requiring promoter demethylation, establishing that NKp30 function extends beyond NK cells through epigenetic reprogramming of adaptors.\",\n      \"evidence\": \"FcεRIγ knockdown/overexpression, promoter methylation analysis, flow cytometry, xenograft tumor model\",\n      \"pmids\": [\"29895693\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FcεRIγ is also limiting for NKp30 on NK cells unresolved\", \"Signaling differences between CD3ζ- and FcεRIγ-coupled NKp30 not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Crystallography of glycosylated NKp30–B7-H6 complex demonstrated that N-glycans drive NKp30 dimerization, providing a structural basis for how glycosylation-dependent oligomerization tunes receptor sensitivity.\",\n      \"evidence\": \"X-ray crystallography of glycosylated complex, enzymatic deglycosylation with size-exclusion chromatography and binding affinity measurements\",\n      \"pmids\": [\"32708305\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether glycan-dependent dimers form on live NK cell surfaces unresolved\", \"Functional consequence of oligomerization for threshold signaling not directly tested in cells\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"IL-2 was identified as a selective regulator of NKp30 (but not NKp46) surface expression, and ectopic overexpression of immunostimulatory NKp30 isoforms rescued anti-tumor cytotoxicity independently of IL-2, revealing isoform-specific functional control.\",\n      \"evidence\": \"IL-2 deprivation assays comparing NKp30 and NKp46, NKp30a/b isoform overexpression, in vivo xenograft model\",\n      \"pmids\": [\"38698855\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which IL-2 selectively controls NKp30 vs NKp46 unclear\", \"Transcriptional vs post-transcriptional regulation of NKp30 isoform switching not fully characterized\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include how NKp30 discriminates activating from inhibitory ligands structurally, how glycan-dependent oligomerization on the live cell surface integrates with adaptor recruitment to set signaling thresholds, and the in vivo contributions of individual NKp30 splice variants to tumor immunosurveillance versus immunosuppression.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of NKp30 bound to an inhibitory ligand (galectin-3, pp65, poxviral HA)\", \"In vivo isoform-specific functions not delineated in genetic models\", \"Relative stoichiometry of CD3ζ vs FcεRIγ in NKp30 complexes on different cell types unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 9, 12, 14]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 7, 37]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 17, 26]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 5, 6, 9, 14, 16, 18]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 14, 17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"B7-H6\",\n      \"BAG6\",\n      \"CD247\",\n      \"FCER1G\",\n      \"LGALS3\",\n      \"ICAM1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}